Adicet Bio vs Nkarta
ACET and NKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACET and NKTX compare
Nkarta is the larger company, worth 3.3 times as much as Adicet Bio ($85.2M against $26.0M).
Nkarta scores higher on the StockData Score (7 against 5 for Adicet Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACET | NKTX |
|---|---|---|
| Size and price | ||
| Market cap | $26.0M | $85.2M |
| Share price | $2.78 | $1.19 |
| Change, 1 year | −74.7% | −39.3% |
| Change, 5 years | −98.1% | −93.1% |
| Beta (5Y) | 1.65 | 1.18 |
| Employees | 102 | 108 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× (better) | 0.4× |
| FCF yield | −309% | −120% (better) |
| Profitability | ||
| Return on equity | −85.9% | −46.6% (better) |
| Return on invested capital | −97.0% (better) | −194% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −1038.6× | – |
| Current ratio | 6.09 (better) | 5.79 |
| Altman Z-score | −8.38 | −3.83 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 65.3% | 82.9% |
| Held by insiders | 92.4% | 35.8% |
| Insider net buying, 12 months | $929K (better) | −$70.4K |
| Short interest, % of float | 64.2% | 8.3% |
Go deeper
- ACET stock overview
- ACET income statement
- ACET valuation and score
- NKTX stock overview
- NKTX income statement
- NKTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.